beta 2-Glycoprotein I (Apolipoprotein H)

A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.

Also Known As:

Networked: 589 relevant articles (3 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Matsuura, Eiji: 25 articles (11/2010 - 01/2002)
2.	Kobayashi, Kazuko: 15 articles (11/2009 - 01/2002)
3.	Shoenfeld, Y: 15 articles (01/2008 - 06/2000)
4.	Lopez, Luis R: 12 articles (05/2010 - 06/2003)
5.	Matsuura, E: 12 articles (05/2010 - 10/2000)
6.	Krilis, Steven A: 10 articles (09/2016 - 01/2002)
7.	Koike, Takao: 10 articles (10/2008 - 01/2002)
8.	de Groot, Philip G: 9 articles (10/2012 - 11/2002)
9.	Atsumi, Tatsuya: 8 articles (01/2016 - 07/2002)
10.	Shoenfeld, Yehuda: 8 articles (08/2007 - 01/2002)

Related Diseases

1.	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/01/2022 - "Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome." 01/01/2016 - "Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome." 04/01/2012 - "Beta2-glycoprotein I gene polymorphisms Val247Leu and Trp316Ser in Spanish patients with primary antiphospholipid syndrome." 07/01/2011 - "Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I." 08/26/2010 - "Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome."
2.	Diabetes Mellitus 10/24/2018 - "BACKGROUND Protective effects of reduced beta 2 glycoprotein I (Rb2GPI) against vascular injury of diabetes mellitus have been extensively investigated. " 05/15/1983 - "[Beta 2 glycoprotein I analysis in patients with hyperlipoproteinemia, arteriosclerotic occlusive disease and diabetes mellitus]." 09/01/2001 - "As apo H is elevated in diabetes mellitus and dyslipidaemia, we wished to test the hypothesis that serum apo H concentration was related to fasting plasma glucose and insulin as well as blood pressure, body mass index, hip/waist ratio and serum lipids in normal individuals. " 05/01/1997 - "To assess the relationship between apolipoprotein H (apo H) plasma levels and lipid metabolism in diabetes mellitus, we have examined the correlation between apo H plasma concentration and the main plasma lipid levels in 127 non-insulin-dependent (NIDDM) and 118 insulin-dependent (IDDM) diabetes mellitus patients. "
3.	Vascular System Injuries 10/24/2018 - "BACKGROUND Protective effects of reduced beta 2 glycoprotein I (Rb2GPI) against vascular injury of diabetes mellitus have been extensively investigated. "
4.	Paraneoplastic Syndromes (Paraneoplastic Syndrome) 01/01/2007 - "Because immunological abnormalities including anti-cardiolipin beta(2) glycoprotein-I antibody improved after surgical resection of BCC, it is likely that APS had occurred as a paraneoplastic syndrome with BCC. "
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/01/1997 - "The dependence of anticardiolipin (aCL) binding on the presence of beta 2-glycoprotein I (beta 2-GPI) as a binding cofactor was assessed in these same groups, and was compared with sera from systemic lupus erythematosus (SLE) patients (n = 11) with raised aCL antibody reactivity. " 05/01/2021 - "Tissue factor (TF) and Human apolipoprotein H (APOH) seem to be significantly associated with a clinical manifestation in systemic lupus erythematosus (SLE) patients with or without APS, mostly because of thrombotic events and coagulation processes. " 09/21/2002 - "[Anti-beta 2-glycoprotein I antibodies and systemic lupus erythematosus]." 03/01/2002 - "Antiphospholipid (APL) antibodies (both anticardiolipin [ACAs] and anti-beta2 glycoprotein I [abeta2GPIs]) were present in 11/34 (32%) of the BD patients and in 54/73 (74%) of Omani patients with systemic lupus erythematosus (SLE) (chi2 = 21.2, P<0.001). " 04/01/2000 - "To investigate T-cell responses to beta(2)GPI, we stimulated PBMC of 18 APS or systemic lupus erythematosus (SLE) patients carrying anti-beta(2)GPI and 10 healthy controls, using a peptide library covering the beta(2)GPI sequence. "

Related Drugs and Biologics

1.	Antibodies
2.	Cardiolipins (Cardiolipin)
3.	Phospholipids (Phosphatides)
4.	LDL Receptors (LDL Receptor)
5.	Antiphospholipid Antibodies
6.	beta 2-Glycoprotein I (Apolipoprotein H)
7.	Anticardiolipin Antibodies
8.	Lupus Coagulation Inhibitor (Lupus Anticoagulant)
9.	Immunoglobulin G (IgG)
10.	Immunoglobulin M (IgM)

Related Therapies and Procedures

1.	Immunomodulation
2.	Orchiopexy
3.	Bariatric Surgery
4.	Kidney Transplantation
5.	Therapeutics